Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

enses

    -- R&D expense:  anticipated to be in a range of approximately $90 to
       $100 million, net of development cost reimbursements under the Roche
       collaboration.  Of this amount, approximately 60 percent is
       attributed to pirfenidone which includes expenses for CAPACITY, RECAP,
       the preparation and support of NDA and MAA submissions and
       manufacturing.

       Approximately 35 percent of the R&D expense is attributed to the
       company's one-third share of all development expenses incurred by the
       collaboration with Roche on ITMN-191.  The balance of 2009 R&D expense
       is related to the advancement of a named pirfenidone analog compound,
       ITMN-520, toward an expected IND filing in mid-2010.

    -- G&A expense: anticipated to be in a range of approximately $35 to $40
       million.  The G&A guidance range includes approximately $5.0 million of
       various pirfenidone pre-launch costs.

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EDT to discuss its financial results for its second quarter and first six months of 2009, its forward-looking financial guidance and its clinical development programs. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 22196018. A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. InterMune to Release Second Quarter Financial Results on August 6
2. InterMune to Present at Goldman Sachs Healthcare Conference
3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release First Quarter Financial Results on April 30
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. InterMune to Present at Canaccord Adams Hepatitis C Conference
7. InterMune to Present at Citis 4th Annual Biotech Day
8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... August 19, 2014 Robin Williams’ passing ... can take on an individual. Symptoms range from ... expression, problems swallowing and severe depression. Parkinson’s disease ... off of dopamine producing neurons of the brain. ... disease that slowly and progressively gets worse, they look ...
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated use of ... new PSUR – responding to the increasing need to understand ... Adopted in many regions, the main objectives of the PBRER ... critical analysis of new or emerging information on the risks ... of the potential benefits of a drug; and , ...
(Date:8/18/2014)... Dallas, Texas (PRWEB) August 19, 2014 ... China Linalool Industry” is a professional and in-depth ... report provides basic Linalool information, including its ... well as industry overview. This research covers the ... well as global industry analysis covering macroeconomic environment ...
(Date:8/18/2014)... Aug. 18, 2014   Sterne, Kessler, Goldstein & ... Washington, DC , announced today that ... Review (IPR) with the U.S. Patent and Trademark ... of BioReference Laboratories, Inc. (Nasdaq: BRLI).  These IPR petitions ... by Myriad Genetics, Inc. These patents have been asserted ...
Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3
... NEW YORK, Sept. 7 Richard Gabriel, Chief,Executive ... DNAG),( http://www.dnaprint.com ) will be featured in an ... to take place on September 10 at 11,a.m. ... http://www.wallst.net by 8 p.m.,EDT on September 10. ...
... Inc. (Nasdaq: HGSI ) announced today that its ... New York will be webcast,and may be accessed at ... A member of Human Genome Sciences, senior management ... September 11, 2007 at 4:00 pm,Eastern Time. Investors ...
... Appeared More Effective Than rituximab ... in a ... GEN) announced today that ofatumumab (HuMax-CD20(R)) appeared more,effective at inducing ... in a pre-clinical study. The CD20,antibodies were incubated with tumor ...
Cached Biology Technology:WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics 2Genmab Announces Encouraging Preclinical Data for ofatumumab 2
(Date:8/19/2014)... August 19, 2014A new ovoid structure discovered in the ... contains a variety of minerals, and shows evidence of ... melting of the permafrost and mixing of surface and ... range of analytical studies to determine the origin of ... how this ovoid formed, point to the most likely ...
(Date:8/19/2014)... analyzed concentrations of African dust transported to South ... spring. These research findings offer new insight on ... of African dust, including the climate change-induced human ... increased African dust emissions in the coming decades., ... School of Marine and Atmospheric Science and colleagues ...
(Date:8/19/2014)... This news release is available in French . ... Stand: balancing the BENEFITS and RISKS of physical activity ... a stand on the promotion of childhood physical activity ... Applied Physiology, Nutrition, and Metabolism ( APNM ... of knowledge in the area of risk of physical ...
Breaking Biology News(10 mins):Life on Mars? Implications of a newly discovered mineral-rich structure 2Study of African dust transport to South America reveals air quality impacts 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3
... may trigger the development of schizophrenia and other bipolar ... Faculty of Biological Sciences (UK) has shown that the ... these disorders by affecting the production of dopamine - ... aspects of movement, cognition and behaviour. Toxoplasmosis, which ...
... in genes which can result in changes in the ... associated with susceptibility to common diseases. In a new ... the Association for Psychological Science, psychologist Tina B. Lonsdorf ... and the University of Greifswald in Germany examined the ...
... fluoride (SO 2 F 2 ), a gas commonly used to ... that remains in the atmosphere about 36 years, six to 10 ... by Jens Mhle, an atmospheric chemist at Scripps Institution of Oceanography, ... the gas rose at a rate of 4 to 6 percent ...
Cached Biology News:Research supports toxoplasmosis link to schizophrenia 2The genetics of fear: Study suggests specific genetic variations contribute to anxiety disorders 2Termite killer lingers as a potent greenhouse gas 2Termite killer lingers as a potent greenhouse gas 3
Normal human serum, single donor...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Human IL-17D Affinity Purified Polyclonal Ab...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Biology Products: